Can stopping migraines before the pain starts work?
NCT ID NCT07310290
Summary
This study is testing if taking the migraine medication ubrogepant during the early 'prodrome' phase—when people first notice warning signs like fatigue or light sensitivity—can prevent moderate or severe headaches from developing over the next 24 hours. It involves about 189 adults in the US who already use ubrogepant for their migraines. Participants will take their prescribed medication as usual during these early signs and track their headache severity for about 13 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chicago Headache Center & Research Inst /ID# 272345
RECRUITINGNaperville, Illinois, 60563, United States
-
Neurology and Pain Specialty Center /ID# 278508
RECRUITINGAliso Viejo, California, 92656, United States
-
Tri City Research Center, LLC /ID# 278800
RECRUITINGGrand Island, Nebraska, 68803, United States
Conditions
Explore the condition pages connected to this study.